High-dose chemotherapy in patients with breast cancer: Evaluation of infusing peripheral blood stem cells containing occult tumor cells

Bone Marrow Transplantation

Volumn 21, Issue 11, 1998, Pages 1117-1124

  Weaver, C H ^a   Moss, T ^b   Schwartzberg, L S ^a   Zhen, B ^a   West, J ^a   Rhinehart, S ^a   Campos, L ^a   Beeker, T ^a   Lautersztain, L ^a   Messino, M ^a   Buckner, C D ^a,c  

^a Response Oncology Inc   (United States)

^b BIS Laboratories   (United States)

^c NONE   (United States)

Author keywords

Breast cancer; Stem cells; Tumor cells

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ADULT; ARTICLE; BONE LESION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; FEMALE; HUMAN; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; TUMOR CELL;

EID: 0031803969     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701247     Document Type: Article

References (36)

1. Ross AA, Cooper BW, Lazarus HM et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82: 2605-2610.
2. Shpall EJ, Jones RB. Release of tumor cells from bone marrow. Blood 1994; 83: 623-625.
3. Shpall EJ, Jones RB, Bearman SI et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 1994; 12: 28-36.
4. Passos-Coelho J, Ross AA, Davis JM et al. Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: effect of ex vivo purging with 4-hydroperoxycyclophosphamide. Cancer Res 1994; 54: 2366-2371.
5. Ross AA. Long-term storage of tumor-involved bone marrow cytopreparations for immunocytochemical analysis. Am J Clin Pathol 1992; 98: 347 (Abstr.).
6. Cote RJ, Rosen PP, Lesser ML et al. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 1991; 9: 1749-1756.
7. Diel IJ, Kaufmann M, Goerner R et al. Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J Clin Oncol 1992; 10: 1534-1539.
8. Sharp JC, Kessinger A, Mann S et al. Detection and clinical significance of minimal tumor cell contamination of peripheral blood stem cell harvests. Int J Cell Clon 1992; 10: 92-94.
9. Harbeck N, Untch M, Pache L, Eiermann W. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. Br J Cancer 1994; 69: 566-571.
10. Fields KK, Elfenbein GJ, Trudeau WL et al. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 1996; 14: 1868-1876.
11. Moss TJ, Cooper B, Lazarus HM et al. Immunocytochemical analysis of bone marrow taken from patients with stage IV breast cancer undergoing autologous transplant therapy. In: Dicke K, Keating A (eds). Autologous Marrow Transplantation. Proceedings of the Eighth International Symposium: University of Texas MD Anderson Hospital and Tumor Institute at Houston, Texas, 1997, pp 467-472.
12. Mansi JL, Berger U, McDonnell T et al. The fate of bone marrow micrometastases in patients with primary breast cancer. J Clin Oncol 1989; 7: 445-449.
13. Vredenburgh JJ, Peters WP, Rosner G et al. Detection of tumor cells in the bone marrow of stage IV breast cancer patients receiving high-dose chemotherapy: the role of induction chemotherapy. Bone Marrow Transplant 1995; 16: 815-821.
14. Passos-Coelho JL, Ross AA, Kahn J et al. Similar breast cancer cell contamination of single-day peripheral-blood progenitor cell collections obtained after priming with hematopoietic growth factor alone or after cyclophosphamide followed by growth factor. J Clin Oncol 1996; 14: 2569-2575.
15. Ybanez J, Lazarus H, Ross A, Cooper B. Impact of occult tumor (OT) reinfusion on outcome after high-dose chemotherapy in patients with advanced breast cancer. Am Soc Hematol 1995; 86: 386a (Abstr.).
16. Stadtmauer E, Sickles C, Mangan P et al. Tumor contamination of stem cells and prognosis in G-CSF mobilized peripheral blood stem cell transplant (PSCT) for responding metastatic breast cancer. Proc Am Soc Clin Oncol 1996; 15: 339 (Abstr.).
17. Brenner MK, Rill DR, Holladay MS et al. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 1993; 342: 1134-1137.
18. + cells present in autologous transplants of chronic myelogenous leukemia contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068-3076.
19. Weaver C, Birch R, Schwartzberg L, West W. High-dose chemotherapy and autologous stem cell transplantation for breast cancer. In: Buckner CD, Clift R (eds). Technical and Biological Components of Marrow Transplantation. Kluwer Academic: Boston, MA, 1995, pp 59-85.
20. Weaver CH, West WH, Schwartzberg LS et al. Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses. Bone Marrow Transplant 1997; 19: 661-670.
21. Schwartzberg L, Birch R, Weaver C et al. Neoadjuvant chemotherapy with or without paclitaxel and high-dose chemotherapy (HDC) with peripheral blood progenitor cell (PBPC) support for locally advanced breast cancer (LABC). Proc Am Soc Clin Oncol 1996; 15: 124 (Abstr.).
22. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
23. Schwartzberg L, Birch R, Hazelton B et al. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. J Hematother 1992; 1: 317-327.
24. Weaver CH, Schwartzberg LS, Birch R et al. Collection of peripheral blood progenitor cells following the administration of cyclophosphamide, etoposide and granulocyte colony-stimulating factor: an analysis of 497 patients. Transfusion 1997; 37: 896-903.
25. Weaver CH, Schwartzberg LS, Birch R et al. Collection of peripheral blood stem cells following the administration of paclitaxel, cyclophosphamide and filgrastim in patients with breast and ovarian cancer. Biol Blood Marrow Transplant 1997; 3: 83-90.
26. Weaver CH, Hazelton B, Palmer PA et al. A randomized dose finding study of filgrastim for mobilization of peripheral blood progenitor cells (PBPCs). P roc Am Soc Clin Oncol 1996; 15: 341 (Abstr.).
27. Weaver CH, Bensinger WI, Appelbaum K et al. Phase I study of high-dose busulfan, melphalan, thiotepa with autologous stem cell support in patients with refractory malignancies. Bone Marrow Transplant 1994; 14: 813-819.
28. Schiffman KS, Bensinger WI, Appelbaum FR et al. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease. Bone Marrow Transplant 1996; 17: 943-950.
29. Ross A, Loudovaris M, Hazelton B et al. Immunocytochemical analysis of tumor cells in pre- and post-culture peripheral blood progenitor cell collections from breast cancer patients. Exp Hematol 1995; 23: 1478-1483.
30. Antman K, Ayash L, Elias A et al. A phase II study of highdose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102-110.
31. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
32. Shpall E, Bast RJ, Jones W et al. Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. Bone Marrow Transplant 1991; 7: 145-151.
33. + marrow cells in patients with breast cancer or neuroblastoma. Blood 1991; 77: 1717-1722.
34. Shpall EJ, Jones RB, Bast RC Jr et al. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. J Clin Oncol 1991; 9: 85-93.
35. Ayash LJ, Wheeler C, Fairclough D et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 1995; 13: 2043-2049.
36. Moss TJ, Cooper B, Kennedy MJ et al. The prognostic value of immunocytochemical (ICC) analysis on bone marrow (BM) and stem cell products (PBSC) taken from patients with stage IV breast cancer undergoing autologous transplant (ABMT) therapy. Proc Am Soc Clin Oncol 1997; 16: 90 (Abstr.).